FibroGen (NASDAQ:FGEN) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a research report on Monday, June 3rd.

FibroGen Trading Up 4.1 %

Shares of FGEN opened at $0.40 on Monday. FibroGen has a twelve month low of $0.33 and a twelve month high of $2.93. The stock’s 50 day moving average is $0.80 and its two-hundred day moving average is $1.33. The firm has a market capitalization of $40.00 million, a PE ratio of -0.16 and a beta of 0.71.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The company had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same quarter in the previous year, the business posted ($0.65) earnings per share. On average, sell-side analysts predict that FibroGen will post -1.05 EPS for the current year.

Insider Buying and Selling

In other news, insider Deyaa Adib acquired 22,123 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was bought at an average cost of $1.17 per share, with a total value of $25,883.91. Following the transaction, the insider now directly owns 82,123 shares in the company, valued at approximately $96,083.91. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.98% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On FibroGen

Several large investors have recently made changes to their positions in the company. Alpine Global Management LLC bought a new position in shares of FibroGen in the first quarter valued at approximately $25,000. Delap Wealth Advisory LLC bought a new position in shares of FibroGen in the first quarter valued at approximately $27,000. Accel Wealth Management bought a new position in shares of FibroGen in the first quarter valued at approximately $103,000. Point72 DIFC Ltd boosted its holdings in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares in the last quarter. Finally, Doheny Asset Management CA bought a new position in shares of FibroGen in the second quarter valued at approximately $48,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.